CHOP Researchers Receive Funding to Study Effects of COVID-19 on Preterm Birth


Excerpt from the article: Researchers at Children’s Hospital of Philadelphia (CHOP) have formed a new consortium that will study the effects of the COVID-19 pandemic on preterm birth and prenatal care, funded by $300,000 in grants from the Independence Blue Cross Foundation, Highmark Blue Cross Blue Shield Delaware’s donor-advised fund, and BluePrints for the Community.…

Read More

Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19


Excerpt from the Press Release: SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today the submission of an Investigational New Drug (IND) to FDA for the investigational use of Tempol for the treatment of Coronavirus (COVID-19). The submission of the IND to FDA followed a Pre-IND meeting with…

Read More

Quebec researchers say they have found an effective drug to fight COVID-19


Excerpt from the Press Release: MONTREAL — A team of researchers from the Montreal Heart Institute believe they have found an effective weapon against COVID-19: colchicine, an oral tablet already known and used for other diseases. For Dr. Jean-Claude Tardif, who led the study, this is a “major scientific discovery,” he said. Colchicine is the…

Read More

Prosetta Biosciences Announces Novel Solution to COVID-19 Crisis


Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Prosetta Biosciences, a San Francisco biotechnology company, has developed novel small-molecule drugs that research indicates are effective not only against the COVID-19 virus, but against other virus families that cause respiratory disease, including influenza and the common cold – without the liability of drug resistance development. The compounds…

Read More

Paragon Genomics NGS Panel Captures New SARS-CoV-2 Mutations


Excerpt from the Press Release: Paragon Genomics, Inc., a leader in amplicon-based target enrichment solutions for next-generation sequencing (NGS) and precision medicine, today announced a solution for capturing the new mutations of the SARS-CoV-2 variants that have been sweeping across the United Kingdom and South Africa, and already finding its way in various countries worldwide.…

Read More

Webinar – Safer Technologies Program: Final Guidance


Summary: On Monday, February 1, 2021, the FDA will host a webinar on the Safer Technologies Program for industry and other stakeholders interested in learning more about the Program and final guidance. Background: The U.S. Food and Drug Administration (FDA) issued a final guidance outlining the Safer Technologies Program for Medical Devices. This program is a…

Read More

Menon Announces Advancement of Trials on Rapid COVID-19 Test at the University of California San Diego


Excerpt from the Press Release: SAN DIEGO, Jan. 19, 2021 /PRNewswire/ — Menon Biosensors, Inc. (“Menon” or the “Company”), a distributive technology portfolio company, announced today that trials will advance on its proprietary Molecular Mirror™ platform technology in collaboration with the University of California San Diego School of Medicine (“UC San Diego”) hoping to prove accuracy…

Read More

Penn Physicist, Physician Team Awarded $2 Million NIH Grant to Develop Portable COVID-19 Detector for Use in Public Spaces


Excerpt from the Article: PHILADELPHIA — A team led by physicists at the University of Pennsylvania and physicians at the University’s Perelman School of Medicine has been awarded a two-year, $2 million grant by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences for the development of a handheld device that can…

Read More

Cyxone reports first Covid-19 patient screened in Phase 2 clinical trial of Rabeximod


Excerpt from the Press Release: STOCKHOLM, Jan. 15, 2021 /PRNewswire/ — Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19. The trial will evaluate the efficacy and safety of oral treatment with Rabeximod to prevent disease progression in hospitalized Covid-19 patients and shorten…

Read More

Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19


Excerpt from the Press Release: LEXINGTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study were randomized within 48 hours of testing positive for COVID-19 to…

Read More